Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Alzheimer's Disease

Clinical Trial Details

Overview

Research Study Summary

A clinical trial seeking patients for a research study for the treatment of Alzheimer's Disease, Dementia or Neurodegenerative Disorders

Research Study Title

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Purpose

Patients with different types of dementia will be recruited and evaluated in national hospital departments for their usual neurological follow-ups. A blood sample will be proposed in the field of this research project, and the biological material will be stored at the DNA and Cell Bank of Institut de Fédératif Recherche (IFR) of Neurosciences (Pitié-Salpêtrière Hospital, Paris). The clinical research network is already set up for Alzheimer's disease and frontotemporal dementias, which permits an evaluation according to a clinical standardized protocol.

Among these disorders, a monogenic sub-group has been identified. In Alzheimer's disease, it is associated with the APP, PSEN1 and PSEN2 genes, which account only for 75% of the familial forms with early onset. In frontotemporal dementias, the tau gene mutations account only for 10% of the cases with an autosomal dominant inheritance. The identification of familial forms with a genetic inquiry in the relatives is essential for a greater knowledge of the molecular bases of forms not caused by the known genes, using linkage approaches and candidate gene analysis. The familial forms are also useful for identifying the modifier genes.

In the multifactorial forms, the aim is to assemble a wide cohort of patients and controls matched for localizing and identifying susceptibility genetic factors. The strategies will use a candidate gene approach, and in the near future, studies of single nucleotide polymorphisms (SNPs) spread out in the whole genome. Meanwhile, similar approaches, particularly with candidate genes, could be used for identifying predictive factors of tolerance and response to the treatment.

Finally, correlations will be performed with seric markers according to each kind of dementia.

Specialized clinical teams in diagnosis and follow-up in dementias are assembled for this project, and in the study of neurological disorders of genetic origin.

To Learn more
Phase

1

Gender

Both Male and Female

Age

18 to 90 Years

Overall Status

Recruiting

Lead Sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Facility Type

N/A

Eligibility

Both Male and Female ages 18 Years to 90 Years

Inclusion Criteria:

  • Patients presenting with a neurodegenerative disorder with cognitive impairment controls (without signs of the disease), matched with sex and age with the patients

  • Relatives for the familial cases

Exclusion Criteria:

  • Pregnant women

  • Minors

  • Persons refusing to sign the informed consent

Site Locations (12)

Country State City Zip Facility and Contact
France Caen 14000 CHU de la Côte de Nacre
Gilles Defer, MD, PhD

Gilles Defer, MD, PhD
Principal Investigator

Isabelle Le Ber, MD
Sub-Investigator
France Marseille 13009 Hôpital Sainte-Marguerite
Bernard-François Michel, MD
0033491744949
bmichel@ap-hm.fr

Bernard-François Michel, MD
Principal Investigator
France Nantes 44000 Hôpital Guillaume et René Laennec
Martine Vercelletto, MD
0033240165422
mvercelletto@chu-nantes.fr

Martine Vercelletto, MD
Principal Investigator
France Nice 06000 Hôpital de l'Archet
Claude Desnuelle, MD, PhD
0033492035505
desnuelle.c@chu-nice.fr

Claude Desnuelle, MD, PhD
Principal Investigator

Marie-Hélène Soriani, MD
Sub-Investigator
France Paris 75013 Pitié-Salpêtrière Hospital - Fédération de Neurologie
Vincent Meininger, MD, PhD
vincent.meininger@psl.aphp.fr

Vincent Meininger, MD, PhD
Principal Investigator

Lucette Lacomblez, MD
Sub-Investigator

François Salachas, MD
Sub-Investigator
France Paris 75013 Pitié-Salpêtrière Hospital - Centre du Langage et de Neuropsychologie
Bruno Dubois, MD
0033142161777
b.dubois@psl.ap-hop-paris.fr

Bruno Dubois, MD
Principal Investigator
France Paris 75013 Pitié-Salpêtrière Hospital
Alexis Brice, MD
0033142162182
brice@ccr.jussieu.fr

Alexis Brice, MD
Principal Investigator

Isabelle Le Ber, MD
Sub-Investigator
France Rennes 35000 Hôpital Pontchaillou
Serge Belliard, MD
0033299284293
belliard.s@voila.fr

Serge Belliard, MD
Principal Investigator

Véronique Golfier, MD
Sub-Investigator
France Rouen 76000 Hôpital Charles Nicolle
Didier Hannequin, MD, PhD
0033232888170
Didier.hannequin@chu-rouen.fr

Didier Hannequin, MD, PhD
Principal Investigator
France Saint-Brieuc 22000 Centre Hospitalier
Véronique Golfier, MD
0033296017454
veronique.golfier@ch-stbrieuc.fr

Véronique Golfier, MD
Principal Investigator
France Saint-Etienne 42000 Hôpital Bellevue
Catherine Thomas-Antérion, MD
0033477127805
catherine.thomas@chu-st-etienne.fr

Catherine Thomas-Antérion, MD
Principal Investigator
France Strasbourg 67000 Hôpital Civil
François Sellal, MD
0033388116892
Francois.Sellal@chru-strasbourg.fr

François Sellal, MD
Principal Investigator

Contact

Alexis Brice, MD
0033142162182
E-mail:

NCT ID: NCT00149175

Date Last Changed: March 12, 2010

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.